This site is intended for healthcare professionals outside of the United States (US) and the United Kingdom (UK).
This site is created and funded by Novartis.
About RLTCare
Your reliable partner for seamless radioligand therapy care
Radioligand therapy (RLT) stands at the forefront of modern cancer treatment, offering hope to patients through targeted nuclear medicine. Yet, the journey to deliver RLT can be long and complex for prescribing and treating physicians.
We are here to ensure you get the help you need every step of
the way.
We have structured our services to simplify the adoption of RLT and minimize time to treatment
Our RLTCare services
About RLT
What is radioligand therapy?
RLT combines a targeting compound, the ligand, that binds to a specific marker, with a radioisotope. The ligand directs the radioisotope to the target cancer cells expressing the specific marker, even when they have spread throughout the body.
This unique mechanism of action aims to damage or destroy target cancer cells or cells of the tumor microenvironment (TME) while limiting impact on nearby healthy cells. This precision approach aims to improve quality of life and extend survival.
See the journey of a dose
Learn how we ensure every dose is delivered with precision from product to patient.
Explore disease areas
With RLTCare, excellent customer service is not just a promise—it is a priority
Get In Touch
Our dedicated RLT specialist teams aim to streamline care coordination and alleviate uncertainty, ensuring you and your patients feel confident and supported every step of the way.